Medicine has always been built on evidence, caution and rigorous validation. That should never change. What must change, however, is how quickly we are able to generate, evaluate and act upon evidence in an increasingly connected world.
There was a time when validating a new medical technology could take years; not necessarily because the technology itself required that amount of time to understand, but because collecting meaningful clinical data was slow, geographically fragmented and dependent on traditional research infrastructure.
That world has changed.
The internet, connected devices, digital health platforms, electronic medical records and increasingly sophisticated data analytics have fundamentally altered the speed at which evidence can be generated. A technology deployed across multiple centres can now generate thousands of observations in real-world settings, while clinicians can communicate almost instantaneously and patients can be followed longitudinally without the constraints that once accompanied paper-based systems and isolated clinical networks.
Consider screening for breast cancer. Traditional mammography-based screening is built around substantial infrastructure: specialised equipment, dedicated facilities, trained radiographers, radiologists and, in many settings, patient travel to centres where this infrastructure exists. It has an established and important role in breast cancer detection, but the model itself is inherently dependent on access to infrastructure.
Now consider a technology such as iBreastExam, a portable, radiation-free breast examination technology designed to enable early detection of breast cancer closer to where women live. Its significance is not simply the technology itself; it is the possibility of changing the architecture of screening. Instead of making the patient travel to the technology, the technology can potentially travel to the patient into primary-care centres, community settings and outreach programmes.
And importantly, iBreastExam should not be viewed as a competitor to mammography, but as a potential pathway to it. By bringing breast screening closer to women who may otherwise never enter the formal screening pathway, it can help identify women who require further evaluation and encourage them to come forward for secondary screening and diagnostic imaging such as mammography or ultrasound. In that context, the technology is not replacing the diagnostic ecosystem, it is helping expand its reach and potentially enabling cancers to be investigated at an earlier stage.
That creates an entirely different evidence-generation paradigm.
When thousands of women can be screened across multiple sites, data can be captured digitally, results can be linked with subsequent imaging or biopsy, and outcomes can be followed systematically, the deployment of the technology itself becomes an opportunity to generate large-scale real-world evidence.
The question therefore should not be whether a new screening technology can be subjected to the same validation discipline as technologies developed decades ago, it absolutely should. The question is whether we need to insist that evidence must be generated using the same timelines and pathways that existed before digital connectivity, distributed healthcare and real-world data.
That distinction matters
Rigour should never be compromised. But duration should not become a proxy for rigour.
A technology should be judged by the quality, reproducibility and clinical relevance of the evidence supporting it, not simply by how long it has existed or how closely its development resembles that of technologies from another era.
The medical establishment has historically been excellent at protecting patients from premature adoption. In the age of rapidly accelerating technology, it must also become equally conscious of the opportunity cost of delayed adoption, particularly when delay means that potentially useful screening tools remain inaccessible to populations that need them most.
There is an important distinction between being cautious and being resistant to change. The former protects medicine. The latter can eventually hold it back. The goal is not to lower the evidentiary bar for innovation. It is to modernise the way we reach that bar.
Because if technology has changed the speed at which evidence can be generated, healthcare must be willing to change the speed at which it evaluates that evidence.
Those who built modern medicine deserve enormous respect for the standards they established. But respecting the past does not require us to be constrained by it. In a world where technology evolves exponentially, intellectual flexibility is no longer optional. It is essential to remaining relevant. Because ultimately, the greatest risk is not adopting something new too quickly.
It is allowing yesterday’s timelines to become tomorrow’s barriers to better healthcare.